🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› EU
Clinical trial register · European Union · CTIS

Recently authorised EU trials

The most recently authorised trials on the EU Clinical Trials Information System (CTIS), the single register for every trial run under the EU Clinical Trials Regulation (536/2014). CTIS holds a far larger historical archive than any one list can usefully show — this register states both numbers rather than picking one.

Download CSV
Source: EMA Clinical Trials Information System (CTIS). Showing the 2500 most recently authorised of 12445 total CTIS records — a stated recency window, not the full historical archive. Synced 20 Sep 2026, 03:17 UTC
2500
Shown in this register
most recently authorised
12,445
Total on CTIS
full historical archive
745
Phase III
within the shown window
Top member states
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524
Narrow the registerReset
Phase
Phase I 558 Phase I/II 214 Phase II 726 Phase III 745 Phase IV 257
Lead sponsor
AstraZeneca AB 60 Assistance Publique Hopitaux De Paris 49 Merck Sharp & Dohme LLC 48 Pfizer Inc. 45 Novo Nordisk A/S 42
Member state
Spain 1023 France 890 Germany 861 Italy 742 Poland 581 Netherlands 524 Belgium 426 Czechia 327
All 28 states
726 of 2500 shown studies
Download
Phase
Study
Lead sponsor
Area
Member states
Decision
Phase II
Epcoritamab in Relapsed/Refractory Marginalzone Lymphoma - A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDY (EPOS-1)
2025-524879-23-00Marginal Zone Lymphoma
Universitaetsklinikum Ulm AöR
Hemic and Lymphatic Diseases
Germany
19/06/2026
Phase II
A randomized, double-blind, placebo-controlled, 104-week proof-of-concept study to evaluate the efficacy of intravenous prasinezumab in participants with Parkinson's disease carrying a severe mutation in the GBA gene (prevent cognitive decline in GBA-associated PD)
2024-513496-40-00PARKINSON’S DISEASE
Universitaetsklinikum Tuebingen AöR
Nervous System Diseases
Spain, Germany, Italy, Sweden, France, Luxembourg
18/06/2026
Phase II
Preventive effect of 5% lidocaine patch on the development of neuropathic pain following an osteoporotic vertebral fracture: A proof-of-concept, controlled, randomized trial
2025-524889-25-00Osteoporotic Fracture
University Hospital Of Clermont-Ferrand
Musculoskeletal Diseases
France
17/06/2026
Phase II
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study of Nemolizumab in Adult Patients with Systemic Sclerosis, including a 52-Week Main Treatment Period and a 156-Week Extension Treatment Period
2025-522294-11-00Systemic sclerosis
Galderma S.A.
Skin and Connective Tissue Diseases
Poland, Italy, Bulgaria, France, Greece, Spain, Croatia
17/06/2026
Phase II
RADICAL-IO: thRee cycles of immunotherApy without raDical therapy In mediCALly InOperable stage I non-small cell lung cancer
2025-524305-32-00Stage I non-small cell lung cancer
Het Nederlands Kanker Instituut-Antoni van Leeuwenhoek Ziekenhuis Stichting
Respiratory Tract Diseases
Netherlands
16/06/2026
Phase II
A Phase 2, Open-Label Long-Term Extension Study in Participants With Duchenne Muscular Dystrophy Amenable to Exon Skipping to Assess the Long-Term Safety, Tolerability, Pharmacokinetics, and Efficacy of Endosomal Escape Vehicle Phosphorodiamidate Morpholino Oligomer Platform Products (ELEVATE-LTE)
2025-525124-10-00Duchenne Muscular Dystrophy
Entrada Therapeutics Inc.
Musculoskeletal Diseases
Belgium, Italy, Netherlands, Spain
16/06/2026
Phase II
A Study to Evaluate the Long-term Safety and Efficacy of Long-acting Antibodies as Single Agents and in Combinations in Participants with Inflammatory Bowel Disease
2025-524640-35-00Ulcerative colitis (Inflammatory Bowel Disease)
Spyre Therapeutics Inc.
Digestive System Diseases
Croatia, Poland, Austria, Czechia, Italy, Slovakia, Bulgaria, Greece, Belgium, Spain, Hungary, Germany, Lithuania, France, Romania
16/06/2026
Phase II
A single arm single center exploratory observational phase II study, aimed to detect long term changes in volume of port-wine macrocheilia and color of port-wine stain in patients undergoing surgery and laser therapy during sirolimus treatment. Quality of life and efficacy and safety of sirolimus will be assessed.
2024-511937-37-01Vascular malfomation
Oslo University Hospital HF
Hemic and Lymphatic Diseases
Norway
15/06/2026
Phase II
A Phase II, Open-label, Multicenter Study Testing Teclistamab in Combination with Pomalidomide Administered in Alternative Fashion in Participants with RRMM, who Received 1 - 3 Prior Lines of Therapy, Including Lenalidomide and Anti-CD38 Therapy
2025-522114-23-00Multiple myeloma (RRMM)
Odense University Hospital
Neoplasms
Finland, Denmark, Estonia, Norway
15/06/2026
Phase II
Exploratory study evaluating the relevance of [68Ga]Ga-FAPI-46 for staging and identifying progressing patients with transthyretin cardiac amyloidosis
2025-523616-36-00Transthyretin cardiac amyloidosis
Centre Hospitalier Universitaire De Nantes
Diagnosis
France
13/06/2026
Phase II
A PHASE 2 STUDY OF STRIDE (durvalumab + tremelimumab) With Lenvatinib Versus STRIDE Alone in Patients With Unresectable Hepatocellular Carcinoma (SLIDE-HCC) - HE.2
2025-521608-23-00patients with unrestectable hepatocellular carcinoma (SLIDE…
IRCCS Istituto Nazionale Tumori Fondazione Pascale
Neoplasms
Italy
12/06/2026
Phase II
J6Z-MC-IIBD - A Master Protocol for Phase 2, Randomized, Controlled Studies of Multiple Interventions for the Treatment of Adults With Moderately to Severely Active Ulcerative Colitis or Crohn’s Disease J6Z-MC-CD01 - A Phase 2, Multicenter, Randomized, Open-Label, Active-Controlled Study to Investigate LY4395089/Mirikizumab Co-administration Compared with Mirikizumab in Adults with Moderately to Severely Active Crohn’s Disease
2025-524112-11-00J6Z-MC-IIBD - Colitis, Ulcerative Crohn Disease J6Z-MC-CD…
Eli Lilly & Co.
Digestive System Diseases
Italy, Germany, Hungary, Poland, Belgium
11/06/2026
Phase II
A Phase 2, Open-Label, Multicenter, Randomized Study to Evaluate Denikitug as Monotherapy or in Combination With Nivolumab or Chemotherapy in Participants With HER2-Negative, Unresectable, Recurrent, and/or Metastatic Gastric, Gastroesophageal Junction (GEJ), and Esophageal Adenocarcinomas
2025-524095-27-00HER2-negative, unresectable, recurrent, and/or metastatic g…
Gilead Sciences Inc.
Neoplasms
Spain, France
11/06/2026
Phase II
J6E-MC-KWAM: A Randomized, Multicenter, Double-Blind, Placebo-Controlled Development Program to Evaluate the Efficacy and Safety of LY4268989 (MORF-057) for the Treatment of Adults with Moderately to Severely Active Ulcerative Colitis (EMERALD-3)
2025-524404-29-00Ulcerative Colitis, Active Severe, Ulcerative Colitis (UC),…
Eli Lilly & Co.
Digestive System Diseases
Latvia, Portugal, Greece, France, Czechia, Italy, Poland, Slovakia, Hungary, Croatia, Lithuania
10/06/2026
Phase II
A multicenter, randomized, double-blind, placebo-controlled, dose-ranging Phase IIb study to assess the efficacy and safety of GIA632 in adult participants with non-segmental vitiligo followed by an extension period
2025-522301-37-00Nonsegmental vitiligo
Novartis Pharma AG
Skin and Connective Tissue Diseases
Germany, Spain, Netherlands, France, Italy
08/06/2026
Phase II
J5D-MC-FPAC: A Phase 2a, Randomized, Multicenter, Double-Blind, Placebo-Controlled Proof of Concept Study to Investigate Efficacy and Safety of LY4005130 in Adult Participants With Severe Alopecia Areata
2025-524727-41-00Alopecia Areata
Eli Lilly & Co.
Immune System Diseases
Poland, Netherlands
08/06/2026
Phase II
A Phase 2, Open Label, Multicenter, Randomized Study, to Evaluate the Efficacy and Safety of Denikitug Monotherapy and Denikitug-based Combinations in Participants With Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC).
2025-523984-39-00Advanced Microsatellite Stable (MSS) Colorectal Cancer (CRC)
Gilead Sciences Inc.
Neoplasms
Spain, Italy, France
08/06/2026
Phase II
REpurposed drug evaluation for DEceleration of immunE aging & Mitigation of chronic inflammation (REDEEM)
2026-526084-38-00Immune Aging, Chronic inflammation
Radboud universitair medisch centrum Stichting
Immune System Diseases
Netherlands
08/06/2026
Phase II
Radium223 dichloride (223RaCl) in the treatment of symptomatic bone metastases from breast cancer.
2025-524208-31-00Symptomatic bone metastases from breast cancer
Azienda Ospedaliera Universitaria Policlinico Paolo Giaccone
Neoplasms
Italy
08/06/2026
Phase II
Evaluating cognitive effects of a three month course of methylphenidate in Parkinson's disease patients with mild cognitive impairment.
2026-525701-12-00Parkinson's disease
Universidad Rey Juan Carlos
Therapeutics
Spain
08/06/2026
Phase II
C4531031 - AN INTERVENTIONAL PHASE 2/3, RANDOMIZED, DOUBLE-BLIND, THIRD PARTY-UNBLINDED, PLACEBO-CONTROLLED, PARALLEL-GROUP STUDY TO INVESTIGATE EFFICACY AND SAFETY OF PF-07275315 IN ADULT PARTICIPANTS WITH MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (COPD)
2024-518587-12-00MODERATE-TO-SEVERE CHRONIC OBSTRUCTIVE PULMONARY DISEASE (C…
Pfizer Inc.
Respiratory Tract Diseases
Spain, Germany, Poland, Czechia, Greece, Italy, Bulgaria, France, Hungary
08/06/2026
Phase II
An open-label, non-randomized, single center, single dose, exploratory phase II trial of FG001 (an imaging agent) in combination with transoral robotic surgery for oropharyngeal squamous cell carcinoma and neck dissection surgery for oral squamous cell carcinoma with regional lymph node metastases
2025-522845-23-00Oral Squamous Cell Carcinoma with neck metastases, Orophary…
Rigshospitalet
Neoplasms
Denmark
08/06/2026
Phase II
Phase II, Single-Center, Randomized, Double-Blind, Placebo-Controlled Clinical Trial To Evaluate The Safety And Efficacy Of Dasatinib To Reduce HIV-1 Reservoir, Chronic Inflammation, And Immune Senescence In People With HIV On Long-Term Antiretroviral Treatment.
2025-524363-20-01HIV-1 infection
Instituto De Salud Carlos III
Virus Diseases
Spain
08/06/2026
Phase II
Phase II, Placebo-controlled trial of Cannabidiol for the treatment of alcohol dependence (PLACONCANALDE)
2023-504439-42-03alcohol dependence
Hospital Universitario 12 De Octubre
Behavioral Disciplines and Activities
Spain
08/06/2026
Phase II
Phase IIb Multicenter Randomized Controlled Trial Evaluating the Efficacy of Sivelestat in Patients with Septic Coagulopathy
2025-523397-16-00Septic Coagulopathy
Les Hopitaux Universitaires De Strasbourg
Investigative Techniques
France
05/06/2026
Rows per page Showing 176–200 of 726
Previous 6 7 8 9 10 Next
Cite this view

Priya Life Science (2026). EU Clinical Trials Register (CTIS), filtered. Derived from the EMA Clinical Trials Information System. Retrieved 20 September 2026. https://priyalifescience.com/clinical-trials-europe

Query this register directly
GET /api/export.php?register=trials-eu&format=json Try it now →
Listing here is informational and not medical advice; eligibility is determined by each study team. Looking for Irish sites? See the Ireland, UK or USA registers. For approved medicines, see the EMA Approvals Tracker.